Home > Name List By other > (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15, 16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione Canada

CAS No 566-48-3 , (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,
16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione Search by region : Canada

  • Name: (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,
    16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
  • Synonyms: 4-Hydroxyandrost-4-ene-3,17-dione; CGP-32349; B;Lentaron;(8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,
    16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione; Aromatase inhibitor; 4-Hydroxyandrostenedione; 4-Hydroxy-4-androstene-3,17-dione;
  • CAS Registry Number:
  • Flash Point: 255.4°C
  • Boiling Point: 475.4°Cat760mmHg
  • Density: 1.19g/cm3
  • Refractive index: 1.545
  • Safety Statements: R60
  • Hazard Symbols: T: Toxic;
  • Flash Point: 255.4°C
  • Molecular Weight: 302.40794
  • InchiKey: OSVMTWJCGUFAOD-KZQROQTASA-N
  • InChI: InChI=1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19
    (12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
  • Risk Statements: S53;S36/37/39;S45
  • Molecular Formula: C19H26O3
  • Molecular Structure:CAS No:566-48-3 (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,<br />16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione

Related products

Select to

566-48-3 FORMESTANE

  • Canada TLC PharmaChem., Inc. [Manufacturer]
  • Tel: 905-760-1098
  • Fax: 905-760-2098
  • Address: TLC PharmaChem., Inc.
    5-150 Connie Crescent
    Concord, Ontario
    L4K 1L9, Canada null,nullCanada
Contact Supplier

Select to

1/1
References of (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,
16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione
Title: Formestane
CAS Registry Number: 566-48-3
CAS Name: 4-Hydroxyandrost-4-ene-3,17-dione
Synonyms: 4-OHA
Manufacturers' Codes: CGP-32349
Trademarks: Lentaron (Novartis)
Molecular Formula: C19H26O3
Molecular Weight: 302.41
Percent Composition: C 75.46%, H 8.67%, O 15.87%
Literature References: Selective aromatase inhibitor. Prepn: R. D. Burnett, D. N. Kirk, J. Chem. Soc. Perkin Trans. 1 1973, 1830; J. Mann, B. Pietrzak, ibid. 1983, 2681; P. G. Ciattini et al., Synth. Commun. 22, 1949 (1992). Aromatase inhibition and effect on estrogen-dependent processes in vivo: A. M. H. Brodie et al., Endocrinology 100, 1684 (1977). Radioimmunoassay in plasma: J. Khubieh et al., J. Steroid Biochem. 35, 377 (1990). GC determn in plasma and urine: P. H. Degen, W. Schneider, J. Chromatogr. 565, 67 (1991). Pharmacokinetics and endocrine effects in breast cancer patients: M. Dowsett et al., Eur. J. Cancer 28, 415 (1992). Clinical evaluation in breast cancer: R. C. Coombes, J. Steroid Biochem. Mol. Biol. 43, 145 (1992).
Properties: Needles from aq methanol, mp 199-202° (Burnett, Kirk); also reported as crystals from ethyl acetate, mp 203.5-206° (Brodie). uv max (99.5% ethanol): 278 nm (e 11030). [a]D20 +181° (c = 7.7 in chloroform).
Melting point: mp 199-202° (Burnett, Kirk); mp 203.5-206° (Brodie)
Optical Rotation: [a]D20 +181° (c = 7.7 in chloroform)
Absorption maximum: uv max (99.5% ethanol): 278 nm (e 11030)
Therap-Cat: Antineoplastic (hormonal).
Keywords: Antineoplastic (Hormonal); Aromatase Inhibitors; Aromatase Inhibitors.